Zevra Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: Form 10-Q, quarterly reportNov 3 →InsidersNo open-market buys. 6 insiders sold $2.5M, 12 of 13 sales on a 10b5-1 plan.→HoldersBlackRock 8.6%FMR 8.3%Woodline Partners 8.1%→Financing →PeersClosest companies: PTCT, MIRM, BBIO→
From the filings
Figures
- Revenue
- $147.8Mlast 12 months
- Net income
- $78.0Mlast 12 months
- Operating cash flow
- $33.4Mlast 12 months
- Cash and equivalents
- $122.1Mat the last balance sheet
- Total debt
- $0.00at the last balance sheet
- Shares outstanding
- 59.4M shareson issue
Filings, newest first
- Nov 310-QQuarterly report
- Nov 38-KResults of operations
- Oct 134Insider trade
- Oct 13144Planned insider sale
- Aug 510-QQuarterly report
- Aug 58-KResults of operations
- Jul 3113GStake over 5%, passive
- Jun 58-KShareholder vote
- May 610-QQuarterly report
- May 68-KResults of operations
- Mar 910-KAnnual report